Cognition Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lisa Ricciardi
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2500 Westchester Avenue Purchase NY United States of America 10577
- IPO Date
- Oct 8, 2021
- CIK
- 0001455365
- Website
- cogrx.com
- Similar Companies
- Business
- Cognition Therapeutics, Inc. Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Founded in 2007 and headquartered in Purchase, New York, the company leverages proprietary biology and chemistry platforms to identify novel drug targets that address dysregulated cellular pathways in neurodegenerative conditions. Its lead product candidate, zervimesine (also known as CT1812), is an orally administered small molecule sigma-2 receptor modulator designed to penetrate the blood-brain barrier, displace toxic protein oligomers from neuronal synapses, and restore normal cellular trafficking functions impaired in diseases such as Alzheimer's disease and dementia with Lewy bodies; zervimesine is currently advancing in Phase 2 clinical trials for these indications, with additional exploration in geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies. The company's pipeline also includes earlier-stage candidates like CT2030, a TREM2-targeted compound for neurodegenerative diseases. In August 2025, Cognition Therapeutics completed a $30 million registered direct offering of common stock to two new institutional investors, including a leading global investment manager, to fund preparation of Phase 3 programs for zervimesine in neurodegenerative disorders, working capital, and general corporate purposes.
Cognition Therapeutics Participating in Upcoming Investor Conferences
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Cognition Therapeutics (NASDAQ:CGTX) CEO Lisa Ricciardi Acquires 9,175 Shares of Stock
Cognition Therapeutics (NASDAQ:CGTX) CFO John Brendan Doyle Buys 10,000 Shares
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Cognition Therapeutics CEO Issues Letter to Shareholders
Cognition Therapeutics Q4 Earnings Call Highlights
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference